IBERE PHARMACEUTICALS

iberepharma.com

No Longer Reporting

The company has not filed an annual or quarterly report since its Q3 FY2022 10-Q, filed Nov 14, 2022. Its latest SEC filing is a 15-12G from Mar 13, 2023.

The sections below describe the company as of the FY2021 annual report.

What Did They Do?

Seeks to merge with or acquire a pharmaceutical or life sciences business.

How Did They Make Money?

No revenue was reported.

How Were They Changing?

Since the FY2021 annual report

Latest quarter: Q3 FY2022, the three months to Sep 30, 2022

Net income: ▼ −54%; vs $1.7M in Q3 FY2021

Feb 15, 2023 Plans to redeem public shares and dissolve after failing to complete a business combination Public shares are scheduled for redemption on March 2, 2023; the company expects its securities to be delisted and registration terminated.

Financial Snapshot

Last updated: 10/28/2026

Size FY2021

Revenue: $0.00
Net Income

Growth FY2021

Revenue Growth: N/A
EPS Growth

Profitability

Gross Margin
Operating Margin
Net Income Margin

Cash flow

Free Cash Flow

Balance sheet FY2021

Cash
Debt to Equity: N/A

Valuation On Mar 7, 2023

Market Cap: $175.61M
P/E: 112.4

Company Facts

Industry: Blank Checks
Incorporated
Headquarters

Comments